Snowden Capital Advisors LLC Has $3.98 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Snowden Capital Advisors LLC lessened its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 7,652 shares of the medical research company's stock after selling 874 shares during the period. Snowden Capital Advisors LLC's holdings in Thermo Fisher Scientific were worth $3,984,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of TMO. Norges Bank purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $3,149,754,000. T. Rowe Price Investment Management Inc. grew its stake in Thermo Fisher Scientific by 86.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after acquiring an additional 1,433,444 shares in the last quarter. Kovitz Investment Group Partners LLC grew its stake in Thermo Fisher Scientific by 1,905.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock valued at $469,889,000 after acquiring an additional 858,193 shares in the last quarter. Proficio Capital Partners LLC grew its stake in Thermo Fisher Scientific by 68,617.0% during the 4th quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock valued at $396,810,000 after acquiring an additional 761,649 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $377,901,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 0.1%

NYSE:TMO traded down $0.45 during mid-day trading on Tuesday, hitting $413.47. The company had a trading volume of 2,141,884 shares, compared to its average volume of 1,845,527. The firm has a market cap of $156.08 billion, a P/E ratio of 25.01, a P/E/G ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The business's fifty day moving average is $451.89 and its two-hundred day moving average is $508.88. Thermo Fisher Scientific Inc. has a fifty-two week low of $390.50 and a fifty-two week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same quarter last year, the firm posted $5.11 earnings per share. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 0.42%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 14,075 shares of company stock worth $7,305,942 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Raymond James reissued an "outperform" rating and issued a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. Citigroup decreased their target price on Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Wells Fargo & Company decreased their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating for the company in a research report on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a "buy" rating in a report on Wednesday, April 23rd. Finally, UBS Group cut their target price on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating for the company in a research note on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Thermo Fisher Scientific presently has an average rating of "Moderate Buy" and a consensus target price of $607.43.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.